RA Capital jumps on board diabetes biotech, pitching in on $160M Series D

A small California biotech is back with more cash and a new big name VC to work with.

Carmot Therapeutics reported a Series D financing worth $160 million Tuesday morning, which the biotech said will be used to push forward and complete clinical studies and advance pre-clinical programs.

Existing backer...

Click to view original post